These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 36670271)
21. Combined Liquid-State and Solid-State Nuclear Magnetic Resonance at Natural Abundance for Comparative Higher Order Structure Assessment in the Formulated-State of Biphasic Biopharmaceutics. Pujahari SR; Mali PS; Purusottam RN; Kumar A Anal Chem; 2023 Jun; 95(22):8469-8477. PubMed ID: 37154614 [TBL] [Abstract][Full Text] [Related]
22. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. Kesselheim AS; Gagne JJ Drug Saf; 2015 Oct; 38(10):849-53. PubMed ID: 26105011 [TBL] [Abstract][Full Text] [Related]
23. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS Drugs; 2017 Mar; 77(4):427-433. PubMed ID: 28181177 [TBL] [Abstract][Full Text] [Related]
24. A comparison of the interaction of glucagon, human parathyroid hormone-(1-34)-peptide and calcitonin with dimyristoylphosphatidylglycerol and with dimyristoylphosphatidylcholine. Epand RM; Epand RF; Orlowski RC; Flanigan E; Stahl GL Biophys Chem; 1985 Nov; 23(1-2):39-48. PubMed ID: 4092081 [TBL] [Abstract][Full Text] [Related]
25. Ultraviolet Resonance Raman spectroscopy used to study formulations of salmon calcitonin, a starch-peptide conjugate and TGF-β3. Patois E; Larmour IA; Bell SE; Palais C; Capelle MA; Gurny R; Arvinte T Eur J Pharm Biopharm; 2012 Jun; 81(2):392-8. PubMed ID: 22421544 [TBL] [Abstract][Full Text] [Related]
26. Chemometric Methods to Quantify 1D and 2D NMR Spectral Differences Among Similar Protein Therapeutics. Chen K; Park J; Li F; Patil SM; Keire DA AAPS PharmSciTech; 2018 Apr; 19(3):1011-1019. PubMed ID: 29110294 [TBL] [Abstract][Full Text] [Related]
27. Solution structure and biological activity of recombinant salmon calcitonin S-sulfonated analog. Wang Y; Dou H; Cao C; Zhang N; Ma J; Mao J; Wu H Biochem Biophys Res Commun; 2003 Jun; 306(2):582-9. PubMed ID: 12804605 [TBL] [Abstract][Full Text] [Related]
28. Solid-State NMR Characterization of Lyophilized Formulations of Monoclonal Antibody Therapeutics. Perodeau J; Arbogast LW; Nieuwkoop AJ Mol Pharm; 2023 Mar; 20(3):1480-1489. PubMed ID: 36702622 [TBL] [Abstract][Full Text] [Related]
29. Dynamic properties of salmon calcitonin bound to sodium dodecyl sulfate micelles: a restrained molecular dynamics study from NMR data. Castiglione Morelli MA; Pastore A; Motta A J Biomol NMR; 1992 Jul; 2(4):335-48. PubMed ID: 1511235 [TBL] [Abstract][Full Text] [Related]
30. Nuclear magnetic resonance chemical shift: comparison of estimated secondary structures in peptides by nuclear magnetic resonance and circular dichroism. Lee MS; Cao B Protein Eng; 1996 Jan; 9(1):15-25. PubMed ID: 9053898 [TBL] [Abstract][Full Text] [Related]
31. Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis. Guerrini M; Rudd TR; Mauri L; Macchi E; Fareed J; Yates EA; Naggi A; Torri G Anal Chem; 2015 Aug; 87(16):8275-83. PubMed ID: 26189325 [TBL] [Abstract][Full Text] [Related]
32. A role for the C-terminus of calcitonin in aggregation and gel formation: a comparative study of C-terminal fragments of human and salmon calcitonin. Moriarty DF; Vagts S; Raleigh DP Biochem Biophys Res Commun; 1998 Apr; 245(2):344-8. PubMed ID: 9571152 [TBL] [Abstract][Full Text] [Related]
33. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610 [TBL] [Abstract][Full Text] [Related]
34. Conformational flexibility in calcitonin: the dynamic properties of human and salmon calcitonin in solution. Amodeo P; Motta A; Strazzullo G; Castiglione Morelli MA J Biomol NMR; 1999 Feb; 13(2):161-74. PubMed ID: 10070757 [TBL] [Abstract][Full Text] [Related]
35. Determination of the conformations of bound peptides using NMR-transferred nOe techniques. Sykes BD Curr Opin Biotechnol; 1993 Aug; 4(4):392-6. PubMed ID: 7763968 [TBL] [Abstract][Full Text] [Related]
36. Use of the 2D Hwang TL; Batabyal D; Knutson N; Wikström M Molecules; 2021 May; 26(9):. PubMed ID: 34063095 [TBL] [Abstract][Full Text] [Related]
38. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391 [TBL] [Abstract][Full Text] [Related]
39. Analytical and statistical comparability of generic enoxaparins from the US market with the originator product. Mourier PA; Agut C; Souaifi-Amara H; Herman F; Viskov C J Pharm Biomed Anal; 2015 Nov; 115():431-42. PubMed ID: 26280926 [TBL] [Abstract][Full Text] [Related]
40. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug. Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]